Skip to Content

Join the 'Acute Myeloid Leukemia' group to help and get support from people like you.

Acute Myeloid Leukemia News

Related terms: Acute Granulocytic Leukemia, Acute Myelogenous Leukemia, ANLL, Cancer, Acute Granulocytic Leukemia, Cancer, Acute Myelogenous Leukemia, Cancer, Acute Myeloid Leukemia, Leukemia, Acute Granulocytic, Leukemia, Acute Myelogenous, Leukemia, Acute Myeloid, AML

Are You Sure That's What the Doctor Said About Your Leukemia?

Posted 3 Nov 2017 by Drugs.com

THURSDAY, Nov. 2, 2017 – The stress of a frightening leukemia diagnosis may impede clear doctor-patient communication, a new study suggests. Patients undergoing chemotherapy treatment for acute myeloid leukemia (AML) tend to view their illness and prognosis through a different lens from their doctors, researchers say. Investigators found that patients are inclined to overestimate their risk of ...

FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia

Posted 1 Sep 2017 by Drugs.com

September 1, 2017 – The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not ...

FDA OKs Return of Once-Withdrawn Leukemia Drug, Mylotarg

Posted 1 Sep 2017 by Drugs.com

FRIDAY, Sept. 1, 2017 – The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia – CD33-positive AML. An earlier version of the drug had been withdrawn from the market when health risks started to emerge. Known generically as gemtuzumab ozogamicin, the drug received the go-ahead to treat adults newly ...

FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia

Posted 3 Aug 2017 by Drugs.com

August 3, 2017 – The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine. “This is the first approved treatment specifically for patients w ...

New Combination Treatment, Vyxeos, Approved for Acute Myeloid Leukemia

Posted 3 Aug 2017 by Drugs.com

THURSDAY, Aug. 3, 2017 – The combination chemotherapy drug Vyxeos (daunorubicin and cytarabine) has been approved by the U.S. Food and Drug Administration as the first treatment for certain high-risk types of acute myeloid leukemia (AML). AML is an aggressive blood cancer that forms in the bone marrow. "Vyxeos combines two commonly used chemotherapies into a single formulation that may help some ...

FDA Approves Idhifa (enasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation

Posted 1 Aug 2017 by Drugs.com

August 1, 2017 – The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. “Idhifa is a ...

Idhifa Approved for Some With Acute Myeloid Leukemia

Posted 1 Aug 2017 by Drugs.com

TUESDAY, Aug. 1, 2017 – Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML). The mutation in the IDH2 gene can be diagnosed with a newly approved companion diagnostic, the RealTime IDH2 Assay, the agency said in a news release Tuesday. "The use of Idhifa ...

Rydapt Approved for Adults With Acute Myeloid Leukemia

Posted 28 Apr 2017 by Drugs.com

FRIDAY, April 28, 2017 – Rydapt (midostaurin) has been approved by the U.S. Food and Drug Administration, in combination with chemotherapy, to treat adults with acute myeloid leukemia (AML) who have a specific genetic mutation dubbed FLT3. AML, a rapidly spreading cancer that forms in the blood marrow and spikes white blood cells, is projected to be diagnosed in just under 20,000 people, and ...

FDA Approves Rydapt (midostaurin) for FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis

Posted 28 Apr 2017 by Drugs.com

April 28, 2017 – The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 ...

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study

Posted 9 Mar 2017 by Drugs.com

WEDNESDAY, March 8, 2017 – The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment – with no signs of additional safety risks, a new study finds. Gleevec – known generically as imatinib – was hailed as a "wonder drug" when it was introduced in 2001 for treating chronic myeloid leukemia (CML). CML is a type of blood cancer that strikes about 5,000 ...

Gene Therapy Helps 2 Babies Fight Type of Leukemia

Posted 25 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 25, 2017 – Two infants with an advanced form of leukemia are in remission after treatment with genetically tweaked immune system cells, British researchers report. Both babies had run out of treatment options for their cancer, known as B-cell acute lymphoblastic leukemia, or ALL. But, after treatment with genetically altered T-cells – a type of immune system cell – both went ...

Ovarian Cancer Drug Rubraca (rucaparib) Given Fast-Track Approval

Posted 19 Dec 2016 by Drugs.com

MONDAY, Dec. 19, 2016 – The anti-cancer drug Rubraca (rucaparib) has been granted accelerated approval by the U.S. Food and Drug Administration to treat advanced ovarian cancer. The approval is limited to cases where the cancer is caused by specific gene mutations known as "deleterious BRCA." BRCA genes normally repair damaged DNA and are designed to prevent tumor growth, the agency said Monday ...

Therapeutic Vaccine Shows 'Game-Changing' Promise Against a Leukemia

Posted 7 Dec 2016 by Drugs.com

WEDNESDAY, Dec. 7, 2016 – An anti-cancer vaccine made from a leukemia patient's own cells can dramatically increase the chance of long-term survival against the deadly disease, a new study indicates. Patients with acute myeloid leukemia – one of the most aggressive blood cancers – must undergo intense chemotherapy to beat back the disease. And then they almost always relapse within a couple of ...

Experimental Immune Cell Rx Shows Promise for Leukemia

Posted 21 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 21, 2016 – An experimental therapy that revs up the immune system's cancer-fighting ability may help treat some leukemia patients who face a grim prognosis, a small study suggests. The treatment involves infusions of "natural killer" (NK) cells taken from a healthy donor and chemically "trained" to go after tumor cells. Researchers found that of nine patients with acute myeloid ...

Exercise May Cut Risk of 13 Cancers, Study Suggests

Posted 16 May 2016 by Drugs.com

MONDAY, May 16, 2016 – Exercise may significantly reduce your risk for many types of cancer, including some of the most lethal forms of the disease, a large review suggests. Working out for even a couple of hours a week appears to shrink the risk of breast, colon and lung cancer, said researchers who looked at 1.4 million adults. "Those are three of the four major cancers that affect Americans ...

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Acute Promyelocytic Leukemia, Leukemia

Related Drug Support Groups

vincristine, cytarabine, decitabine, daunorubicin, Idhifa, Oncovin, Cytosar, Cytosar-U, Mylotarg, view more... gemtuzumab, Vyxeos, Cerubidine, cytarabine liposomal / daunorubicin liposomal, Idamycin PFS, Vincasar PFS, enasidenib, Tarabine PFS, midostaurin, idarubicin, Idamycin, Rydapt